Preview: Henry Schein’s Earnings

Henry Schein (NASDAQ:HSIC) is set to give its latest quarterly earnings report on Monday, 2023-08-07. Here’s what investors…

Henry Schein (NASDAQ:HSIC) is set to give its latest quarterly earnings report on Monday, 2023-08-07. Here’s what investors need to know before the announcement.

Analysts estimate that Henry Schein will report an earnings per share (EPS) of $1.25.

Henry Schein bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.02, which was followed by a 1.86% increase in the share price the next day.

Here’s a look at Henry Schein’s past performance and the resulting price change:

Quarter Q1 2023 Q4 2022 Q3 2022 Q2 2022
EPS Estimate 1.23 1.21 1.14 1.16
EPS Actual 1.21 1.21 1.15 1.16
Price Change % 1.86% 0.39% -2.87% -1.28%

eps graph

Stock Performance

Shares of Henry Schein were trading at $78.31 as of August 03. Over the last 52-week period, shares are up 2.72%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Henry Schein visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY

Cannabinoids-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) reported on Tuesday year-end 2023 results and audited financial statements. The Canadian company reported CA$16.8 million ($12.3 million) in total revenue, up by 314% year-over-year. Avicanna mostly attributed a surge in revenue to the acquisition of Medical Cannabis by Shoppers from Shoppers Drug Mart and the launch of MyMedi.ca. "2023 was a tremendous year for Avicanna where we solidified our leadership position in the Canadian medical cannabis sector through our proprietary products and the launch of MyMedi.ca," he said. "We have successfully demonstrated the scalability of our revenues and made significant improvements in our fundamentals while advancing all our business pillars."

AVCNF